Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. seizsafe

SEIZSAFE SIGNED

Patient-self-adaptive system for detection, recording and alert to caregivers of night-time seizures, linked to private cloud platform for patient tracking and big data exploitation.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SEIZSAFE project word cloud

Explore the words cloud of the SEIZSAFE project. It provides you a very rough idea of what is the project "SEIZSAFE" about.

putting    million    seizure    recurrent    epilepsy    2022    suffer    suffering    usually    generalized    inconveniences    night    expand    medical    innovative    encore    market    video    stance    convulsions    worsens    resting    certain    illness    bad    constant    self    risk    2m    relatives    cardiac    detect    patient    reduce    seizures    validation    lives    device    privacy    monitor    unobtrusive    seizsafe    active    patients    population    people    approximately    techniques    record    camera    caregivers    diagnosed    globally    consists    proportion    injured    considering    alert    prescribed    sleep    tracking    bedroom    time    big    global    learning    algorithm    foresees    size    cloud    worldwide    arrest    private    platform    1000    rest    5    daptive    drugs    doctors    linked    data    adaptive    detection    holding   

Project "SEIZSAFE" data sheet

The following table provides information about the project.

Coordinator		 ENCORE LAB SL 

Organization address
address: AVDA ZARAGOZA 18, 1º OF. 2
city: LOGRONO
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.seizsafe.com
 Total cost 856˙375 €
 EC max contribution 599˙462 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENCORE LAB SL ES (LOGRONO) coordinator 599˙462.00

Map

 Project objective

Approximately 50 million people worldwide have epilepsy, an illness characterized by recurrent seizures. The estimated proportion of the general population with active epilepsy is between 4 and 10 per 1000 people. Globally, an estimated 2.4 million people are diagnosed with epilepsy each year. When patients suffer generalized convulsions there is a risk for them of being injured or having a cardiac arrest. Caregivers (usually patients’ relatives) reduce this risk by being alert and applying techniques such as holding the patients, putting them in a certain stance or providing them with the prescribed drugs. The problem worsens when seizures occur at night-time. Caregivers usually sleep in the same bedroom as patients and cannot rest due to the constant concern, leading to inconveniences such as loss of privacy, bad resting and higher risk for patients. This project aims to improve the lives of people affected by epilepsy, both patients and caregivers, providing them with an effective and unobtrusive device to monitor patients and alert caregivers during night-time seizures. This project consists on a patient-self-daptive system to detect, video-record and alert caregivers of night-time seizures, linked to a private cloud platform for medical tracking of patients and big data exploitation. The main innovative characteristics of SEIZSAFE are: • Patient-self-adaptive and self-learning algorithm for seizure detection • Camera and cloud platform for doctors • Reduced-cost technology • Medical validation The present project aims to expand SEIZSAFE in the European market. Considering a global market size of 1.2M epilepsy patients suffering night-time seizures, ENCORE foresees the uptake of 6.5% of the market in 5 years, which means 80,000 users by the end of 2022.

 Deliverables

List of deliverables.
Validation reports Documents, reports 2019-07-24 10:26:39
Class I medical device CE mark Demonstrators, pilots, prototypes 2019-07-23 17:24:03
Documentation in different languages Websites, patent fillings, videos etc. 2019-07-22 08:17:36
Conference proceedings Websites, patent fillings, videos etc. 2019-07-22 08:17:38
Technical documentation of SeizSafe Other 2019-02-26 15:20:06
User manual Websites, patent fillings, videos etc. 2019-02-26 15:20:09

Take a look to the deliverables list in detail:  detailed list of SEIZSAFE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEIZSAFE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEIZSAFE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More